孟加拉国农村健康成人两剂戊型肝炎病毒疫苗方案的免疫原性与安全性:一项随机、双盲、对照的2期/先导试验
在孟加拉国农村纳入100名16-39岁健康成人,按1:1随机接受两剂戊型肝炎(HEV)疫苗或乙型肝炎(HBV)对照疫苗(0、1月接种)。HEV 239疫苗不良事件与对照疫苗相当、程度轻微,研究组全部血清转化且抗体至少维持两年,结论为两剂方案可产生广泛且可能具有功能性的免疫应答,安全性可接受,在孟加拉国农村开展4期研究可行。
要点
- HEV 239疫苗两剂方案(0、1月)在健康成人中全部血清转化,抗体至少维持两年。
- 不良事件与HBV对照疫苗相当,程度轻微,1至9天内缓解。
- 接种后1个月可检测到T细胞应答。
核心结论
- 两剂HEV 239疫苗可产生广泛且可能具有功能性的抗HEV免疫应答,至少维持两年,安全性可接受,在孟加拉国农村开展4期研究可行。
研究设计与样本
- 随机、双盲、对照的2期/先导试验,纳入100名16-39岁健康男性和非妊娠女性,按1:1随机接受两剂HEV疫苗或HBV对照疫苗(0、1月接种)。
- 于第0天、第60天及接种后2年采集血样。
- 主要终点为第一剂后2个月内不良事件的比例和严重程度,以及抗HEV IgG水平从第0天至第60天及接种后2年的纵向变化。
主要发现
- HEV 239疫苗的不良事件与对照疫苗相当,程度轻微,1至9天内缓解。
- 研究组全部参与者血清转化,并达到高水平HEV IgG抗体,除一人外所有人两年后抗体仍为阳性。
- HEV 239疫苗接种后1个月可检测到T细胞应答。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis E virus (HEV) is a major cause of acute viral hepatitis worldwide and it contributes to considerable maternal and neonatal mortality and morbidity in many low-income countries like Bangladesh. A three-dose regimen of a vaccine against HEV (HEV 239) has shown promising results in China. The effects and safety of this vaccine in other populations and with different dosing regimens remains uncertain. OBJECTIVES: Investigate the immune response and safety of a two-dose regimen with the HEV 239 vaccine among healthy adults. Examine the feasibility of conducting a larger HEV 239 vaccine trial in rural Bangladesh. METHODS: One-hundred healthy men and non-pregnant women 16-39 years old were randomized in a 1:1 ratio to receive two doses of either the study (HEV) or control (Hepatitis B virus, HBV) vaccine (at 0, 1 month). Blood samples were collected at day 0, day 60 and 2 years after vaccination. The primary endpoints were the proportion and severity of adverse events up to 2 months after dose one and the longitudinal shift in anti-HEV IgG levels from day 0 to day 60 and 2 years after vaccination. RESULTS: Adverse events to HEV 239 were comparable to the control vaccine, mild in severity and resolved within one to nine days. All participants in the study group seroconverted and achieved high levels of HEV IgG antibodies that remained positive for two years in all but one. A T-cell response was detected one month after HEV 239 vaccination. CONCLUSION: Our results show that two doses of the HEV 239 vaccine produces broad and likely functional immune responses against HEV that remain for at least two years. The safety profile was acceptable and a phase four study of HEV 239 in rural Bangladesh is feasible. CLINICALTRIALS: gov Identifier: NCT02759991.
引用
- Øverbø J, Aziz A, Zaman K, et al. Immunogenicity and safety of a two-dose regimen with hepatitis E virus vaccine in healthy adults in rural Bangladesh: A randomized, double-blind, controlled, phase 2/pilot trial. Vaccine. 2023. PMID: 36599736. doi:10.1016/j.vaccine.2022.12.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。